Sapien Biosciences selected for Rejig.HydStartups Corporate Market Access and Investor Program

 

Rejig.HydStartups has selected 100 start-ups for programs that help them reposition their business models post-pandemic. Sapien Biosciences is one of the lucky companies selected for the Corporate Market Access and Investors Program.

 

https://www.newindianexpress.com/cities/hyderabad/2020/aug/04/rejig-hydstartups-handpicks-100-startups-for-mega-mentorship-project-2178672.html

Our CEO, Dr. Jugnu Jain, wins Niti-Aaayog’s Women Transforming India Award on International Women’s Day, March 2020.

https://www.youtube.com/watch?v=Grg30L36B50

 

The Women Transforming India (WTI) Awards is NITI Aayog’s annual initiative to highlight the commendable and groundbreaking endeavours of India’s women leaders and changemakers. In 2018, the Awards were brought under the aegis of NITI Aayog’s Women Entrepreneurship Platform (WEP) and have had a special focus on entrepreneurship ever since. Through the WTI Awards, NITI Aayog hopes to celebrate and bring to the national platform exceptional women entrepreneurs who have broken the glass ceiling with their grit and determination.

The Fourth Edition of the WTI Awards built on last year’s theme of ‘Women and Entrepreneurship’ was announced in August 2019. NITI Aayog received over 2300 applications from across the country in November, 2019. On 8th March 2020, the Top 15 women entrepreneurs were awarded at the Women Transforming India Awards ceremony held at Sushma Swaraj Bhawan in New Delhi.

Sapien’s breast cancer database showcased @BioAsia2020, shortlisted by an expert selection committee for Startup Stage @ BioAsia 2020.

 

 

 

 

Sapien Biosciences team @ BioAsia 2020, at Stall # S14. Sapien was selected from the Startup Stage competition and awarded free exhibit space and delegate pass at BioAsia. Here we showcased several breast cancer patients’ tissue-derived in vitro models for testing new drugs and markers at Sapien. The deep database of ~10,000 Indian breast cancer patients’ data was also showcased. These data can be used for developing Artificial Intelligence-based algorithms to improve the diagnosis, treatment and survival of future breast cancer patients.

Dr Jain of Sapien selected to participate at Global Entrepreneurs Summit 2019 at the Hague, NL

Dr. Jugnu Jain, Co-Founder and CEO of Sapien Biosciences, has been selected to participate in the Global Entrepreneur Summit (GES), 3-5th June 2019, at the Hague in Netherlands. Our biobank will represent India in the area of Health at the summit. We have also been invited to the select discussion with the U.S. Department of Health and Human Services Deputy Secretary Eric D. Hargan and CEO of Royal Philips, Frans van Houten, on Health Policy and Innovation.

Sapien will be showcased in front of a select group of decision makers, including funders, founders, experts and policymakers. Leading American, European, Asian and global companies alongside institutional investors such as APG and PGGM have committed to take part in the GES.

As GES website states – it gathers governments, the private sector and a powerful partner network to turn challenges into business opportunities worldwide. It is co-hosted by two of the world’s most innovative countries, the United States and the Netherlands.

2019 is the 9th edition of GES, which will focus on global opportunities for the next wave of entrepreneur-led innovation in scalable enterprises. We have reached out to other Healthpreneurs at the summit and look forward to meeting them.

https://www.ges2019.org/

http://sapienbio.com/

 

Panel discussion on Innovation at the Academia Industry Synergy Day at NIPER-Hyderabad

NIPER Hyderabad had a star-studded Academia-Industry Synergy day on 23rd Aug, 2018. I was asked to moderate apanel on Innovation and Entrepreneurship. I chose to focus on the aspect of driving innovation already at NIPER-H towards commercialization. Invited Dr. Ashutosh of NIPER to identify where the gaps are, and put them to a panel of seasoned people drawn from industry in different areas of expertise spanning from technology transfer, chemistry, determining cell and animal model activity, development of pharmaceutical properties etc.

In the picture above, taken with the Director of NIPER, from left to right, my expert panellists were

  1. a) Sreenivas, ex-P&G, ex-Lilly, who started Sreeni Labs 11 years ago,
  2. b) Suresh Poosala, ex-BMS who just started OncoSeek Bio,
  3. c)Myself, ex-Vertex, who co-founded Sapien Biosciences and Saarum Sciences,
  4. d) Shashi Bala Singh, Director of NIPER-Hyd
  5. e) Anil Wali, FIIT
  6. f) Hemant Bhutani, ex-NIPER-Mohali, BMS-BBRC
  7. g) Ashutosh Kumar, ex-NIPER-Mohali, Associate Professor at NIPER-H

Dr. Suman Kapur of BITS-Pilani Hyd, had to leave early but she shared her challenges and experience of developing point of care diagnostic devices.

Many useful suggestions came from not just the panel but also students and members of the audience. These will be compiled and used to continue the dialogue with NIPER-H to see how best to implement them.

Establishment of glioma patient derived 3D culters to evaluate the potency of drugs compared to 2D model

Attended Regional Young investigator meeting, Hyderabad (18th – 19th August, 2018) at University of Hyderabad. Sapien Biosciences presented importance of primary human patient cultures, especially spheroid (3D) for drug testing in Glioblastoma multiforme. We have identified molecules that demonstrated differential anti-cancer activity between 2D and 3D cultures in functional readouts including cancer stem cells.

Drug Tested in Glioblastoma